Table 2. Correlation analysis between RAE1 and clinicopathological features.
| Allred score 3 |
Allred score 5 |
|||||
|---|---|---|---|---|---|---|
| <3 | ≥3 | p-value | <5 | ≥5 | p-value | |
| n = 73 | n = 25 | n = 82 | n = 16 | |||
| Tumour size | 0.397 | 0.794 | ||||
| ≤2 cm | 45 (61.6%) | 13 (52.0%) | 49 (59.8%) | 9 (56.3%) | ||
| >2 cm | 28 (38.4%) | 12 (48.0%) | 33 (40.2%) | 7 (43.8%) | ||
| Lymph node | 0.537 | 1.000 | ||||
| Negative | 41 (56.9%) | 16 (64.0%) | 48 (59.3%) | 9 (56.3%) | ||
| Positive | 31 (43.1%) | 9 (36.0%) | 33 (40.7%) | 7 (43.8%) | ||
| Unknown | 1 | 0 | ||||
| Histologic grade | 0.187 | 0.013 | ||||
| I, II | 46 (63.0%) | 12 (48.0%) | 53 (64.6%) | 5 (31.3%) | ||
| III | 27 (37.0%) | 13 (52.0%) | 29 (35.4%) | 11 (68.8%) | ||
| Oestrogen receptor | 0.947 | 0.343 | ||||
| Negative | 18 (24.7%) | 6 (24.0%) | 22 (26.8%) | 2 (12.5%) | ||
| Positive | 55 (75.3%) | 19 (76.0%) | 60 (73.2%) | 14 (87.5%) | ||
| Progesterone receptor | 0.469 | 0.865 | ||||
| Negative | 29 (39.7%) | 12 (48.0%) | 34 (41.5%) | 7 (43.8%) | ||
| Positive | 44 (60.3%) | 13 (52.0%) | 48 (58.5%) | 9 (56.3%) | ||
| HER2 | 0.729 | 0.548 | ||||
| Negative | 46 (63.9%) | 15 (60.0%) | 52 (64.2%) | 9 (56.3%) | ||
| Positive | 26 (36.1%) | 10 (40.0%) | 29 (35.8%) | 7 (43.8%) | ||
HER2, human epidermal growth factor receptor 2.